Curated News
By: NewsRamp Editorial Staff
May 04, 2026
Ventripoint Showcases AI Cardiac Imaging at AEPC 2026
TLDR
- Ventripoint's VMS+ 4.0 provides MRI-equivalent cardiac measurements faster and cheaper, giving clinicians a competitive edge in patient management.
- VMS+ uses AI to analyze echocardiograms, producing volumetric cardiac measurements with MRI accuracy, streamlining workflows and reducing assessment time.
- Ventripoint's technology improves lifelong care for congenital heart disease patients by enabling early, accurate, and accessible cardiac assessments.
- Ventripoint will exhibit at AEPC 2026 in Padua, Italy, showcasing VMS+ 4.0 which integrates AI to enhance pediatric cardiology.
Impact - Why it Matters
This news matters because it highlights a significant advancement in the management of congenital heart disease (CHD), a lifelong condition affecting millions worldwide. Ventripoint's VMS+™ technology offers a non-invasive, affordable, and accurate alternative to MRI for assessing cardiac function, enabling earlier and more frequent monitoring. For patients with CHD, this means improved clinical outcomes through personalized care pathways, as clinicians can track changes in heart function over time with confidence. The integration of AI-driven analysis at the point of care reduces delays in diagnosis and treatment, potentially lowering healthcare costs and improving quality of life. As CHD patients live longer due to medical advances, tools like VMS+™ are essential for lifelong surveillance, making this innovation a game-changer in pediatric and congenital cardiology.
Summary
Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) is set to showcase its innovative cardiac imaging technology at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. AEPC, founded in 1963, is the world's largest association in congenital cardiology, uniting over 1,000 specialists from 32 European countries and beyond. This year's meeting is hosted by the University of Padova and centers on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is making significant strides. The company will exhibit alongside its European distributor, AngioPro, engaging with clinicians from the global congenital cardiology community.
A key focus at the Ventripoint booth will be the VMS+™ system, which enables tracking of cardiac function over time in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which emphasize CHD as a lifelong condition requiring structured follow-up and echocardiography as the primary modality for assessing ventricular function. Ventripoint's priority for 2026 is accelerating the integration of VMS+™ into routine practice, with the latest release, VMS+™ 4.0, designed to streamline workflows and reduce assessment time, making advanced cardiac analysis accessible at the point of care. The system provides volumetric cardiac measurements equivalent to MRI from a patient's first echocardiogram, supporting clinical decision-making throughout a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.” Ventripoint is an industry leader in applying artificial intelligence to echocardiography, and its VMS+™ product family, powered by proprietary KBR technology, holds regulatory approvals in the U.S., Europe, and Canada. For more details, view the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Ventripoint Showcases AI Cardiac Imaging at AEPC 2026
